Investor Presentation

Transcription

1 Investor Presentation September 12, 2018 Nasdaq: ATRA

2 Forward-Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, product candidates, regulatory approvals, the initiation, timing, progress and results of preclinical studies and clinical trials and our research and development programs, ability to sell, manufacture or otherwise commercialize our product candidates, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, any royalty payments, and our ability to obtain and maintain intellectual property protection for our product candidates, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important risk factors are described more fully under the heading Risk Factors in Atara s quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 1, 2018, including the documents incorporated by reference therein and subsequent filings with the SEC. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Atara's own internal estimates and research. While Atara believes these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of Atara s internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based onsuch internal estimates and research. The content of this presentation is subject to copyright, which will be asserted by Atara and no part of this presentation may be reproduced, stored in a retrieval system, or transmitted in any form or by any means without prior permission in writing from Atara. 2

3 Building a Leading Off-the-Shelf, Allogeneic T-Cell Immunotherapy Company Transform the lives of patients with serious medical conditions Tab-cel for blood cancers and solid tumors; FDA Breakthrough & EMA PRIME designations MS first T-cell immunotherapy in development outside the field of oncology Next Gen CAR T designed to address current CAR T technology limitations Late Stage Validated Targets Innovative Technology Platform World-class T cell manufacturing Tab-cel (tabelecleucel); MS: Multiple Sclerosis; CAR T: chimeric antigen receptor T-cell 3

4 A Pioneer in Off-the-Shelf T-Cell Immunotherapy At an Inflection Point INNOVATIVE TECHNOLOGY PLATFORM ADVANCING TAB-CEL IN HEMATOLOGIC & SOLID TUMORS EXPANDING T-CELL IMMUNOTHERAPY TO AUTOIMMUNE DISORDERS DEVELOPING NEXT GEN CAR T IMMUNOTHERAPY Proprietary off-the-shelf T-cell immunotherapy technologies Versatile therapeutic applications Two Phase 3 EBV+ PTLD studies ongoing Phase 1/2 NPC PD-1 combo study planned in 2018 Encouraging early results in progressive multiple sclerosis Off-the-shelf MS data expected in 1H19 Leverages off-theshelf T-cell platform Novel CAR T technology & target collaborations Initial IND expected in 2H19 NPC: Nasopharyngeal carcinoma; CMV: Cytomegalovirus; BKV: Virus isolated from a renal transplant patient with initials B.K.; JCV: John Cunningham Virus 4

5 Innovative Proprietary Off-the-Shelf, Allogeneic T-Cell Immunotherapy Technology Platform Allogeneic engineering T-Cell Manufacturing Cell Selection Algorithm Two complementary technologies 1) EBV-specific T cell platform 2) Next gen CAR T collaborations Scalable production processes One lot yields therapy for multiple patients Match patients to most efficacious T-cell line Based on over a decade of clinical experience HLA: human leukocyte antigen 5

6 Developing Innovative Therapeutic Advantages for Off-the-Shelf T-Cell Immunotherapies Available in 3-5 days with T-cells delivered from inventory Streamlined pretreatment required Precision targeting with limited off target activity Two hour monitoring following short IV infusion 6

7 Robust Pipeline with Multiple T-Cell Immunotherapy Product Candidates in Clinical Development Indication/Program Target Preclinical Phase 1 Phase 2 Phase 3 Registration RR EBV+ PTLD following HCT (1) EBV MATCH EU tab-cel (tabelecleucel) RR EBV+ PTLD following SOT EBV 1 st line EBV+ PTLD EBV EAP: RR PTLD and other EBV+ cancers (2) EBV ALLELE planned Nasopharyngeal carcinoma (3) EBV planned MS Portfolio Autologous ATA190 Progressive MS Allogeneic ATA188 Progressive MS and RRMS EBV (4) EBV (4) planned ATA230 Refractory CMV Infection and Disease Post HCT/SOT CMV CAR T Pipeline AML; B-cell malignancies; Solid tumors; Autoimmune & infectious diseases Multiple Other Programs ATA520; ATA621; ATA368 WT1 BK/JCV HPV RR: Rituximab refractory EAP: Expanded Access Protocol (1) Expect to submit conditional marketing authorization in EU, Phase 3 in US (2) Including solid tumors (3) Phase 1/2 study in combination with Merck's anti-pd-1 therapy, KEYTRUDA (pembrolizumab), in patients with platinum-resistant or recurrent EBV associated NPC is planned for (4) Targeted antigen recognition technology 7

8 A Pioneer in Off-the-Shelf T-Cell Immunotherapy At an Inflection Point INNOVATIVE TECHNOLOGY PLATFORM ADVANCING TAB-CEL IN HEMATOLOGIC & SOLID TUMORS EXPANDING T-CELL IMMUNOTHERAPY TO AUTOIMMUNE DISORDERS DEVELOPING NEXT GEN CAR T IMMUNOTHERAPY Proprietary off-the-shelf T-cell immunotherapy technologies Versatile therapeutic applications Two Phase 3 EBV+ PTLD studies ongoing Phase 1/2 NPC PD-1 combo study planned in 2018 Encouraging early results in progressive multiple sclerosis Off-the-shelf MS data expected in 1H19 Leverages off-theshelf T-cell platform Novel CAR T technology & target collaborations Initial IND expected in 2H19 8

9 Initial Focus On Epstein-Barr Virus (EBV) The Original Oncovirus (1) Background Associated Diseases Present in >95% of individuals by age 40 Persistent lifelong, asymptomatic infection Infects B-cells and epithelial cells Implicated in a wide range of cancers and autoimmune diseases (2) Infectious mononucleosis (mono) Post transplant lymphoproliferative disorder (PTLD) Other hematologic malignancies (e.g. Burkitt s/hiv-related lymphomas) Nasopharyngeal carcinoma (NPC) Other solid tumors (e.g. gastric cancer) Growing evidence for role in the pathogenesis of multiple sclerosis (MS) (3) (1) Young LS, Rickinson AB. Nat Rev Cancer Oct;4(10): (2) EBV vascular latent membrane protein-1 (LMP-1) positive cells (red arrowheads, membrane and endocytic vesicle immunohistochemistry staining) are shown in chronic active MS plaque from archived brain sample. Han MH, Moreno MA, Or-Geva N, Aftab BT, Croze E, Khanna R, Steinman L. MSParis 2017 Congress, the 7th Joint ECTRIMS/ACTRIMS Meeting. (3) Epstein-Barr virus (Ralwel/Shutterstock.com) 9

10 Potential to Transform Treatment of RR EBV+ PTLD Patient with Rituximab Refractory EBV+ PTLD Following HCT (1) One Year Survival from Phase 2 Clinical Studies Conducted at MSK (2) EBV+ PTLD following HCT 68% EBV+ PTLD following SOT 64% ~23% N = 35 36% N = 14 NEW Week 0 CR after 4 cycles Progression following treatment with rituximab (3 cycles) Complete response (CR) following treatment with tab-cel Expected survival in RR PTLD (3) tab-cel Expected survival in RR PTLD (4) tab-cel Expected survival in EBV+ PTLD following HCT after rituximab failure is days (3) MSK: Memorial Sloan Kettering Cancer Center (1) 36 year old woman with Fanconi anemia; Radiographic results from Phase 2 clinical study patient provided for illustrative purposes only to show how the clinical parameters above may correlate to the clinical presentation of a patient. (2) Few treatment-related serious adverse events (SAEs): 12 possibly related Serious Adverse Events (SAEs) among 173 patients: no infusion related toxicities, no CRS (cytokine release syndrome) and three possibly related graft vs. host disease (GvHD); Safety data on file as of December Prockop, S., et al. EHA (3) Atara estimated 1 year survival based on analysis of Ocheni S, et al. Bone Marrow Transplantation 2008 Aug;42(3): (4) 36% at 1yr and 0% at 2yrs in patients with high-risk PTLD treated with rituximab without chemotherapy; Choquet S., et al. Ann Hematol Aug;86(8):

11 Tab-cel First Off-the-Shelf T-Cell Immunotherapy In Phase 3 Clinical Development In the U.S. Multicenter EAP findings from the Phase 3 populations were consistent with previously reported studies conducted by MSK (1) 80% EAP Study ORR 83% N = 5 N = 6 Phase 3 Primary Endpoint is ORR N ~ 35 FDA Agreement on Phase 3 design (2) Global, multicenter, open-label 35 patients per indication Response rate primary endpoint First Phase 3 results and EU CMA submission expected in H HCT SOT 37% MATCH - HCT ALLELE - SOT (2) ORR hurdle Early EU reimbursement discussions in UK, Germany and France (3) Planning tab-cel Phase 3 study in first-line EBV+ PTLD ORR of 37% would result in a Phase 3 study that meets the primary endpoint (4) EAP: Expanded Access Protocol; ORR: overall response rate; CMA: Conditional Marketing Authorization (1) Prockop, S., et al. ASH (2) MATCH: EBV+PTLD following HCT after failure of rituximab (N=35); ALLELE: EBV+PTLD following SOT after failure of rituximab (N = 35) and after failure of rituximab + chemo (N = 35); Cohorts enroll concurrently and are not comparative; Treatment regimen: 2x10 6 cells/kg weekly for 3 wks followed by 2 wks rest. (3) Health Technology Assessment (HTA) agencies participated in EMA Scientific Advice meeting, conducted under PRIME designation. (4) The protocols are designed to rule out 20% ORR as the null hypothesis. For example, assuming anticipated enrollment of 35 patients in MATCH, an ORR above approximately 37% would be expected to meet the primary endpoint. In ALLELE, each of two cohorts with an anticipated enrollment of 35 patients will be analyzed independently using the same statistical methodology. 11

12 Tab-cel Compelling Value Proposition in EBV+ PTLD High and durable response data (1) Off-the-shelf 10%-15% pediatric population Costeffective therapy (2) Tab-cel Value Proposition Low cost of administration Repeat dosing & cell line switching Few treatment related serious events Potential to minimize risk of graft loss (3) (1) Prockop S, et al., Proc ASCO 2015; Atara data on file. (2) Initial Atara value-based assessment (3) Franke AJ, et al. Proc. ASCO

13 Tab-cel for Solid Tumors Targeting EBV Associated Metastatic Nasopharyngeal Carcinoma (EBV+ NPC) Overview Head and neck cancer that is primarily EBV associated Patients have competent immune function Focused on metastatic/recurrent NPC Addressable Patients 2014 Metastatic/Recurrent EBV+ NPC (1) Standard Treatment Platinum-based chemotherapy +/- targeted therapy Median overall survival is 5-11 months (2) Unmet Need 1,500 deaths annually in the US and EU5 (3) No approved targeted agents today Additional 93,000 addressable patients in Asia, with the vast majority in China (1) EU5 (3) 4,200 US 5,200 (1) The metastatic/recurrent drug-treatable population is the total of newly diagnosed stage IV incident cases and patients from earlier stages who failed prior chemoradiation therapy; Atara market research. (2) Ma, et al. Cancer Sci Jul;99(7):1311-8; Hsu OncLive conference coverage, 2015 European Cancer Congress. (3) Globocan 2012; EU5: United Kingdom, France, Germany, Italy and Spain 13

14 Encouraging Tab-cel Phase 1 Monotherapy Results in Patients with Advanced Metastatic NPC 11 of 14 metastatic NPC patients alive with median 18 month follow-up (1) Few treatment-related SAEs Tab-cel expanded after administration without pre-treatment Results highlight tab-cel activity in solid tumor and immuno-competent patients Tab-cel Clinical Activity in metastatic/2l+ NPC (1) 84% EBV upregulates the transcription of PD-L1 in EBV associated solid tumors U.S. FDA accepted IND to initiate tab-cel Phase 1/2 study in combination with anti-pd-1 21% Overall Response Rate Two Year Overall Survival Plan to start tab-cel Phase 1/2 study in combination with Merck s KEYTRUDA in H (2) PD-1: programmed death receptor-1 (1) Prockop, S, et al., Proc ASCO 2016; 21% ORR includes one complete response and two partial responses (2) Phase 1/2 study in combination with Merck's KEYTRUDA (pembrolizumab), in patients with platinum-resistant or recurrent EBV associated NPC; April 2017 agreement where Merck will provide drug supply to Atara; Study will be conducted by Atara and will evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination 14

15 A Pioneer in Off-the-Shelf T-Cell Immunotherapy At an Inflection Point INNOVATIVE TECHNOLOGY PLATFORM ADVANCING TAB-CEL IN HEMATOLOGIC & SOLID TUMORS EXPANDING T-CELL IMMUNOTHERAPY TO AUTOIMMUNE DISORDERS DEVELOPING NEXT GEN CAR T IMMUNOTHERAPY Proprietary off-the-shelf T-cell immunotherapy technologies Versatile therapeutic applications Two Phase 3 EBV+ PTLD studies ongoing Phase 1/2 NPC PD-1 combo study planned in 2018 Encouraging early results in progressive multiple sclerosis Off-the-shelf MS data expected in 1H19 Leverages off-theshelf T-cell platform Novel CAR T technology & target collaborations Initial IND expected in 2H19 15

16 Growing Evidence that EBV Has a Major Role in the Pathogenesis of Multiple Sclerosis CD8+ T-Cell Function Loss of EBV specific CD8+ T-cell function correlates with MS disease progression EBV infection sharply increases risk of development of MS (1) More EBV infected B-cells and plasma cells found in brains of MS patients (2) Close proximity to areas of active demyelination Genetic factors influence loss of EBV specific CD8+ T-cells and correlate with MS progression (3) Low vitamin D also suppresses CD8+ T-cells and is associated with MS (4) (3) Health Relapsing MS Progressive MS Age Auto-reactive EBV infected B-cells thought to accumulate in the CNS (5) (1) MS risk Increases sharply following EBV infection; Levin LI, et al. Ann Neurol Jun;67(6): (2) Moreno MA, Or-Geva N, Aftab BT, Khanna R, Croze E, Steinman L, Han MH. Neurol Neuroimmunol Neuroinflamm Jun 7;5(4) (3) Data source, Pender MP. Neuroscientist 2011; 17: (4) Kuhle J. Mult Scler Jul;21(8): (5) Immortalized EBV infected B-cells produce pathogenic autoantibodies and provide costimulatory survival signals to autoreactive T-cells 16

17 Clinical Activity of Autologous ATA190 in Progressive MS Durable Response of Over 3 Years in 1 st Patient Treated Clinical Findings Gd-Enhanced MRI Single patient who originally received 4 escalating doses Reduction in fatigue, painful lower limb spasms Improvement in cognition, hand function and work productivity No serious adverse events Symptomatic improvements were sustained for 3.5 years First patient retreated in Phase 1 study (1) Baseline After ATA190 T-cell immunotherapy Gd-Enhanced MRI: Gadolinium-enhanced magnetic resonance imaging (1) Pender MP, et al. MSParis 2017 Congress, the 7th Joint ECTRIMS/ACTRIMS Meeting 17

18 Autologous ATA190 Demonstrated Encouraging Results in 10 Progressive MS Patients (1) Reduction in fatigue was a consistent observation in responding patients 26 weeks 6 weeks of treatment and 20 weeks of F/U Patients Experienced Improvement Improvements Correlate with EBV Reactivity Encouraging EDSS Results Well Tolerated 6 experienced clinical improvement 2-14 weeks after initial treatment 5 of the 6 patients who experienced clinical improvement received ATA190 with 7% EBV reactivity 3 patients improved EDSS score (2) 0 treatment-related serious adverse events observed Multicenter Phase 1 allogeneic ATA188 study in MS patients ongoing; Randomized autologous ATA190 progressive MS study expected to start in 2019 EDSS: Expanded Disability Status Scale (1) Pender et al. MSParis 2017 Congress, the 7th Joint ECTRIMS/ACTRIMS Meeting (2) EDSS 5 to 4.5, 5 to 3.5 and 6.5 to 6; 10%-15% of PPMS patients expected to have worsening of EDSS at 24 weeks (Montalban et al NEJM) 18

19 A Pioneer in Off-the-Shelf T-Cell Immunotherapy At an Inflection Point INNOVATIVE TECHNOLOGY PLATFORM ADVANCING TAB-CEL IN HEMATOLOGIC & SOLID TUMORS EXPANDING T-CELL IMMUNOTHERAPY TO AUTOIMMUNE DISORDERS DEVELOPING NEXT GEN CAR T IMMUNOTHERAPY Proprietary off-the-shelf T-cell immunotherapy technologies Versatile therapeutic applications Two Phase 3 EBV+ PTLD studies ongoing Phase 1/2 NPC PD-1 combo study planned in 2018 Genetically engineered T-cell immunotherapies Encouraging early results in progressive multiple sclerosis Leverages off-theshelf T-cell platform Novel CAR T technology & target collaborations Initial IND expected in 2H19 19

20 Evolution of CAR T Landscape Multiple Next Generation & Off-the-Shelf Technology Opportunities CAR T immunotherapy today Future CAR T opportunities High response in advanced hematologic malignancies Disease relapse in some patients Limited efficacy in solid tumors Autologous manufacturing & logistics Long vein-to-vein time High real-world failure rate Constrained capacity Narrow patient eligibility Pre-treatment with chemotherapy Safety: CRS & neurotoxicity Curative intent Solid tumors & earlier lines of therapy Autoimmune & infectious diseases Strategies to address resistance Off-the-shelf inventory manufactured in advance from healthy donors Rapid delivery to every eligible patient Streamlined pre- and post-treatment care and monitoring Improved safety & tolerability CAR T: chimeric antigen receptor T-cell 20

21 Advantages of EBV-Specific T-Cell Immunotherapy Platform to Develop Off-the-Shelf CAR T Products TCR Increased T cell persistence No gene editing or HLA edits required Maintaining donor T-cell advantages HLA EBV-specific T cell EBV T-cells may be immunologically privileged Limited impact of negative immuno-regulatory elements Virally-directed T cells proliferate and produce inflammatory cytokines in presence of T regs (1) Expand in immuno-competent patients without lymphodepleting chemotherapy pre-treatment (2) Low risk of GvHD or CRS Established EBV-specific T cell clinical profile (1) Maeda Y, et al. Science Dec 19;346(6216): ; Regulatory T cells (Tregs) silence T cells with reactivity to self (2) Prockop S, et al. Proc ASCO

22 Next Generation T-Cell Engineering Technologies Designed to Address Current CAR T Limitations Expanded targets and diseases of interest Hematologic & solid tumors: Initial focus in AML and B-cell malignancies Autoimmune, infectious diseases Strategies with potential to overcome resistance Multi targeted CARs to prevent antigen loss resistance & increase specificity PD-1 dominant negative receptor to shield T cell from checkpoint inhibition Viral vector CAR 1 CAR 2 More physiologic T-cell signaling designed to improve persistence and safety Novel modified CD28 and 41BB co-stimulation domains PD-1 DNR PD-1: Programmed Death receptor-1 22

23 Atara s Off-the-Shelf CAR T Strategy: Engineer Next Generation CAR Technologies in EBV-specific T Cells Clinically validated EBV-specific off-the-shelf T-cell platform Next generation CAR technologies Off-the-shelf CAR T with broad applications 23

24 Collaboration with Moffitt Cancer Center to Develop Multi-Targeted CAR T Immunotherapies AND Logic CAR T Activation OR Logic CAR T Activation Research collaboration with Marco Davila, M.D., Ph.D. to develop next generation CAR T immunotherapies Multi-targeted CARs for AML and B-cell malignancies with potential to: Address receptor heterogeneity found frequently in AML Overcome antigen loss resistance Avoid targeting of healthy tissues expressing only one target Novel CAR signaling domains designed to improve proliferation by reducing exhaustion and enhancing persistence Multi-targeted CAR T activation technology for AML and B-cell malignancies (1) Antigen T cell Normal cells Activated T cell Cancer cells Multiple targets selected for AML and B-cell malignancy CAR T programs AML: Acute Myeloid Leukemia (1) Hanada K, Restifo NP. Double or nothing on cancer immunotherapy. Nat Biotechnol Jan;31(1):

25 Expanded MSK Collaboration for Next Generation CAR T Immunotherapies in Multiple Diseases Collaboration includes multiple CAR T targets in oncology, autoimmune and infectious diseases Novel CAR T genetic constructs that we believe have physiologic T-cell activation properties Leveraging Atara s off-the-shelf, allogeneic T-cell immunotherapy technology platform, manufacturing expertise and R&D capabilities New CAR T technologies seek to overcome persistent therapeutic challenges, such as safety and tolerability, durability of treatment response, and activity in areas of significant unmet medical need that are underserved by the current generation of CAR T immunotherapies. Michel Sadelain, M.D., Ph.D. Director, Center for Cell Engineering Memorial Sloan Kettering Cancer Center 25

26 New Atara CAR T Preclinical Pipeline Expanding with Novel Technology Collaborations Program Indication Target CAR T Technologies Collaborator ATA2321 AML Dual-targeted undisclosed Novel co-stimulation domains (1) ATA2431 B-cell malignancies Multi-targeted CD19-CD20- CD22 Novel co-stimulation domains (1) ATA3219 B-cell malignancies CD19 Off-the-shelf, allogeneic Novel co-stimulation domain Atara program Solid tumors Undisclosed PD-1 DNR Novel co-stimulation domain Other Programs Autoimmune disease Undisclosed Novel co-stimulation domain Infectious disease Undisclosed Novel co-stimulation domain Preclinical activities ongoing with initial CAR T IND expected in H DNR: Dominant Negative Receptor (1) Development expected to start in autologous setting 26

27 Clear Strategic Focus and Goals Near-Term Complete tab-cel RR PTLD Phase 3 Launch tab-cel Progress first novel CAR T into clinical development Mid-Term Generate Phase 2 POC data in multiple sclerosis Advance tab-cel + KEYTRUDA in NPC (solid tumor) CAR T clinical results in blood cancers & solid tumors Longer-Term Leverage power of the platform Off-the-shelf, allogeneic CAR T immunotherapies Autoimmune and viral diseases New CAR T collaborations POC: Proof-of-concept 27

28 Multiple Key Milestones Expected in Next 12 Months Opened first U.S. site for ongoing allogeneic ATA188 study in patients with progressive MS March 2018 Present long-term tab-cel Phase 2 clinical outcomes for patients with EBV+ PTLD at EHA 2018 June 2018 Announced collaborations with MSK & Moffitt Cancer Center to advance novel CAR T immunotherapies Mid 2018 Initiate tab-cel Phase 1/2 NPC study in combination with Merck's anti-pd-1 therapy, KEYTRUDA H Present updated tab-cel results in patients with EBV+ cancers H Submit EU conditional marketing authorization in patients with EBV+ PTLD following HCT who failed first-line therapy H First tab-cel Phase 3 study results expected H Announce initial results from allogeneic ATA188 study in patients with progressive MS H

29 A Pioneer in Off-the-Shelf T-Cell Immunotherapy At an Inflection Point Company Potential first approved off-the-shelf T-cell immunotherapy Developing global commercial plan and world-class manufacturing capabilities Well-capitalized: Cash and investments of $417.0 million at June 30, 2018 Net proceeds of $340.9 million raised in 2018; 45.3 million shares outstanding (1) Tab-cel Realizing the global value of EBV associated cancers EBV+ PTLD: Entered Phase 3; Planning for EU launch Encouraging solid tumor activity and safety in NPC Pipeline Advancing robust pipeline of high potential candidates Multiple CAR T programs leveraging Atara T-cell platform & next gen technology MS: ATA188 Phase 1 ongoing; Expect randomized ATA190 study to start in 2019 Future Recognized as a leader in off-the-shelf T-cell immunotherapy Leverage platform s power in other cancer, autoimmune and viral diseases Potential BD activities; Genetically engineered T-cell immunotherapies (1) As of July 27,